OncoCyte Overview

  • Founded
  • 2009

Founded
  • Status
  • Public

  • Employees
  • 115

Employees
  • Stock Symbol
  • OCX

Stock Symbol
  • Investments
  • 5

  • Share Price
  • $0.98

  • (As of Thursday Closing)

OncoCyte General Information

Description

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Contact Information

Ownership Status
Publicly Held
Financing Status
Pending Transaction (M&A)
Primary Industry
Diagnostic Equipment
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
NAS
Primary Office
  • 15 Cushing
  • Irvine, CA 92618
  • United States
+1 (949) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoCyte Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.98 $0.95 $0.81 - $5.48 $119M 125M 474K -$0.72

OncoCyte Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 90,761 162,105 158,526 109,684
Revenue 8,064 7,727 1,216 0
EBITDA (63,182) (68,944) (30,540) (22,374)
Net Income (68,276) (64,097) (29,932) (22,426)
Total Assets 171,051 159,563 55,419 39,859
Total Debt 4,547 5,677 8,632 5,936
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoCyte Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OncoCyte‘s full profile, request access.

Request a free trial

OncoCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnos
Diagnostic Equipment
Irvine, CA
115 As of 2021
000.00
000000000 000.00

000000

uis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 00000

000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000 000000000
Redwood City, CA
0000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoCyte Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DermTech Formerly VC-backed San Diego, CA 000 00000 000000000 00000
00000000 000000 Formerly VC-backed Redwood City, CA 0000 00000 000000 - 000 00000
0000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 000000&0 00000
000000000 Venture Capital-Backed Siena, Italy 00 0000000000 0
00000000 Venture Capital-Backed Seattle, WA 00 0000 00000000000 0000
You’re viewing 5 of 34 competitors. Get the full list »

OncoCyte Patents

OncoCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20130295581-A1 Methods and compositions for the treatment and diagnosis of breast cancer Abandoned 04-May-2012 00000000000 0
US-20150018235-A1 Methods and compositions for the treatment and diagnosis of pancreatic cancer Abandoned 13-Jan-2012 000000000000
US-20140357518-A1 Methods and compositions for the treatment and diagnosis of thyroid cancer Abandoned 12-Jan-2012 0000000000
AU-2012203810-B2 Methods and compositions for the treatment and diagnosis of bladder cancer Ceased 22-Jun-2011 0000000000 0
EP-2723898-A4 Methods and compositions for the treatment and diagnosis of bladder cancer Withdrawn 22-Jun-2011 C12Q1/6886 0
To view OncoCyte’s complete patent history, request access »

OncoCyte Executive Team (12)

Name Title Board Seat Contact Info
Ronald Andrews Chief Executive Officer & Board Member
William Annett Chief Executive Officer & Board Member
Mitchell Levine Chief Financial Officer, Finance
Gisela Paulsen Chief Operating Officer, Operations
Douglas Ross Ph.D Chief Scientific Officer
You’re viewing 5 of 12 executive team members. Get the full list »

OncoCyte Board Members (9)

Name Representing Role Since
Alfred Kingsley JD Self Board Member 000 0000
Andrew Arno OncoCyte Chairman & Board Member 000 0000
Andrew Last Ph.D Self Board Member 000 0000
Jennifer Carter MD Self Board Member 000 0000
Melinda Griffith JD Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

OncoCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoCyte Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OncoCyte‘s full profile, request access.

Request a free trial

OncoCyte Investments & Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 19-Apr-2021 0000000000 000.00 Laboratory Services (Healthcare) 000000 00
00000 0000000 25-Feb-2021 0000000000 0000 Diagnostic Equipment 000000 00
0000000 00000 31-Jan-2020 0000000000 0000 Biotechnology 000000 00
00000 0000000 05-Sep-2019 000000000 0000 Diagnostic Equipment 00000000
Cell Targeting 28-Jan-2011 Merger/Acquisition 00.00 Biotechnology
To view OncoCyte’s complete investments and acquisitions history, request access »

OncoCyte Subsidiaries (2)

Company Name Industry Location Founded
Razor Genomics Diagnostic Equipment Brisbane, CA 2014
0000000 00000000 Biotechnology Nashville, TN 0000
To view OncoCyte’s complete subsidiaries history, request access »